These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 18575732

  • 1. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
    Kawaoka T, Oka M, Takashima M, Ueno T, Yamamoto K, Yahara N, Yoshino S, Hazama S.
    Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
    [Abstract] [Full Text] [Related]

  • 2. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.
    Kondo H, Hazama S, Kawaoka T, Yoshino S, Yoshida S, Tokuno K, Takashima M, Ueno T, Hinoda Y, Oka M.
    Anticancer Res; 2008 Jul; 28(1B):379-87. PubMed ID: 18383873
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y.
    Clin Cancer Res; 2008 Oct 15; 14(20):6487-95. PubMed ID: 18927288
    [Abstract] [Full Text] [Related]

  • 7. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
    Shindo Y, Hazama S, Maeda Y, Matsui H, Iida M, Suzuki N, Yoshimura K, Ueno T, Yoshino S, Sakai K, Suehiro Y, Yamasaki T, Hinoda Y, Oka M.
    J Transl Med; 2014 Jun 19; 12():175. PubMed ID: 24947606
    [Abstract] [Full Text] [Related]

  • 8. Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2.
    Yoshino I, Yano T, Murata M, Ishida T, Sugimachi K, Kimura G, Nomoto K.
    Cancer Res; 1991 Mar 01; 51(5):1494-8. PubMed ID: 1997188
    [Abstract] [Full Text] [Related]

  • 9. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient.
    Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A.
    J Immunol; 1994 Sep 01; 153(5):2102-9. PubMed ID: 8051415
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. CTL in mice immunized with human mucin 1 are MHC-restricted.
    Apostolopoulos V, Loveland BE, Pietersz GA, McKenzie IF.
    J Immunol; 1995 Dec 01; 155(11):5089-94. PubMed ID: 7594517
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo.
    Mukherjee P, Ginardi AR, Tinder TL, Sterner CJ, Gendler SJ.
    Clin Cancer Res; 2001 Mar 01; 7(3 Suppl):848s-855s. PubMed ID: 11300482
    [Abstract] [Full Text] [Related]

  • 14. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    Cancer; 2009 Feb 15; 115(4):800-11. PubMed ID: 19117353
    [Abstract] [Full Text] [Related]

  • 15. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B, He Y, Sun DL, Zou Y, Qin XH, Huang BH.
    Zhonghua Yi Xue Za Zhi; 2008 Jul 22; 88(28):1956-60. PubMed ID: 19062734
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.
    Barratt-Boyes SM, Vlad A, Finn OJ.
    Clin Cancer Res; 1999 Jul 22; 5(7):1918-24. PubMed ID: 10430099
    [Abstract] [Full Text] [Related]

  • 18. [Adoptive immunotherapy using MUC1--specific CTLs for unresectable pancreatic cancer].
    Kawaoka T, Takashima M, Yamamoto K, Ueno T, Oka M.
    Nihon Rinsho; 2006 Jan 22; 64 Suppl 1():279-82. PubMed ID: 16457266
    [No Abstract] [Full Text] [Related]

  • 19. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer in vitro.
    Chen J, Guo XZ, Li HY, Zhao JJ, Xu WD.
    World J Gastroenterol; 2017 Feb 07; 23(5):817-829. PubMed ID: 28223726
    [Abstract] [Full Text] [Related]

  • 20. Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.
    Ohmura Y, Yoshikawa K, Saga S, Ueda R, Kazaoka Y, Yamada S.
    Oncol Rep; 2008 May 07; 19(5):1265-70. PubMed ID: 18425386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.